Show simple item record

dc.contributor.authorKaratas, Hulya
dc.contributor.authorAktas, Yesim
dc.contributor.authorGursoy-Ozdemir, Yasemin
dc.contributor.authorBodur, Ebru
dc.contributor.authorYemisci, Muge
dc.contributor.authorCaban, Secil
dc.contributor.authorVural, Atay
dc.contributor.authorPinarbasli, Onur
dc.contributor.authorCapan, Yilmaz
dc.contributor.authorFernandez-Megia, Eduardo
dc.contributor.authorNovoa-Carballal, Ramon
dc.contributor.authorRiguera, Ricardo
dc.contributor.authorAndrieux, Karine
dc.contributor.authorCouvreur, Patrick
dc.contributor.authorDalkara, Turgay
dc.date.accessioned2019-12-10T11:24:17Z
dc.date.available2019-12-10T11:24:17Z
dc.date.issued2009
dc.identifier.issn0270-6474
dc.identifier.urihttps://doi.org/10.1523/JNEUROSCI.4246-09.2009
dc.identifier.urihttp://hdl.handle.net/11655/15636
dc.description.abstractCaspases play an important role as mediators of cell death in acute and chronic neurological disorders. Although peptide inhibitors of caspases provide neuroprotection, they have to be administered intracerebroventricularly because they cannot cross the blood-brain barrier (BBB). Herein, we present a nanocarrier system that can transfer chitosan nanospheres loaded with N-benzyloxycarbonyl-Asp( OMe)-Glu(OMe)-Val-Asp(OMe)-fluoromethyl ketone (Z-DEVD-FMK), a relatively specific caspase-3 inhibitor, across BBB. Caspase-3 was chosen as a pharmacological target because of its central role in cell death. Polyethylene glycol-coated nanospheres were conjugated to an anti-mouse transferrin receptor monoclonal antibody (TfRMAb) that selectively recognizes the TfR type 1 on the cerebral vasculature. We demonstrate with intravital microscopy that this nanomedicine is rapidly transported across the BBB without being measurably taken up by liver and spleen. Pre-or post-treatment (2 h) with intravenously injected Z-DEVD-FMK-loaded nanospheres dose dependently decreased the infarct volume, neurological deficit, and ischemia-induced caspase-3 activity in mice subjected to 2 h of MCA occlusion and 24 h of reperfusion, suggesting that they released an amount of peptide sufficient to inhibit caspase activity. Similarly, nanospheres inhibited physiological caspase-3 activity during development in the neonatal mouse cerebellum on postnatal day 17 after closure of the BBB. Neither nanospheres functionalized with TfRMAb but not loaded with Z-DEVD-FMK nor nanospheres lacking TfRMAb but loaded with Z-DEVD-FMK had any effect on either paradigm, suggesting that inhibition of caspase activity and subsequent neuroprotection were due to efficient penetration of the peptide into brain. Thus, chitosan nanospheres open new and exciting opportunities for brain delivery of biologically active peptides that are useful for the treatment of CNS disorders.
dc.language.isoen
dc.publisherSoc Neuroscience
dc.relation.isversionof10.1523/JNEUROSCI.4246-09.2009
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectNeurosciences & Neurology
dc.titleA Nanomedicine Transports A Peptide Caspase-3 Inhibitor Across The Blood-Brain Barrier And Provides Neuroprotection
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalJournal Of Neuroscience
dc.contributor.departmentNöroloji
dc.identifier.volume29
dc.identifier.issue44
dc.identifier.startpage13761
dc.identifier.endpage13769
dc.description.indexWoS
dc.description.indexScopus


Files in this item

This item appears in the following Collection(s)

Show simple item record